OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)
Closed Solicitation Posted
- Solicitation number
- CBD254-011
- Agency
-
Joint PEO Chemical and Biological Defense
Acquisition Support Center, Department of Defense
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- More information
Notice details come from DoD SBIR/STTR (DSIP). Updated .
About this opportunity
The Department of the Army Acquisition Support Center, Joint PEO Chemical and Biological Defense, solicited Phase I proposals under open topic CBD254-011, Expeditionary Biologics-on-Demand (BOND), with a response deadline of May 13, 2026, which has passed as of today. The set-aside is Total Small Business.
The topic seeks a portable, high-performance BOND system for point-of-care protein production that maximizes purity, potency, and quality through automated process control, soft sensors, machine learning, and real-time analytics. Phase I is a feasibility study using an existing BOND platform. The attached FY25.4 Release 12 announcement, as summarized by GovTribe AI, describes Phase II as a ruggedized, portable system producing GMP-like protein with weekly batch production and verified consistent quality, and Phase III as an FDA-ready device. Phase II proposals may be submitted no sooner than five months after Phase I award. The same announcement caps Phase I awards at $209,575.00 for up to six months of performance.
Proposals go through the Defense SBIR/STTR Innovation Portal (DSIP) and must include a coversheet, a technical volume of 20 pages maximum in at least 10-point font, a cost volume, a Company Commercialization Report, supporting documents, Fraud Waste and Abuse training completion, and a foreign affiliations disclosure form. Offerors must disclose any foreign nationals, green card holders, or dual citizens involved, and may be restricted under ITAR or EAR. The topic is marked ITAR: No. Research involving human subjects, animal subjects, or recombinant DNA requires separate DoD-level approval beyond institutional review boards.
Selection is based on scientific and technical quality as determined by a Technical Evaluation Team. The NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the PSC is AC12, National Defense R&D Services.
Notice text
DoD SBIR topic CBD254-011
Component: CBD
Command: CBD
Phase: SBIR Program Phase I Action
Technology Areas: Bio Medical; Chem Bio Defense
Focus Areas: Biotechnology
Keywords: Protein; Manufacturing; Therapeutics; Diagnostics; Protection
ITAR: No
Objective:
Develop a portable, high-performance BOND system for point-of-care protein production by maximizing protein purity, potency, and quality. This can be achieved through automated process control, incorporating soft sensors, machine learning, and real-time data analytics to predictively and autonomously adjust production parameters for optimal yield.
Description:
On-demand distributed protein production offers significant advantages, including the creation of diverse therapies, vaccines, diagnostics, and detection biologics. It also streamlines delivery, eliminates cold-chain requirements, reduces R&D costs, and enables rapid scaling for better supply-demand matching1.
Deployable, modular BOND systems can enhance supply chain resilience and broaden medical countermeasure capabilities by enabling on-site protein production in forward-deployed locations. Similar to the impact of 3D printing on manufacturing, these compact systems offer a transformative approach to producing medical treatments where they are needed. Such technologies may enable multi-nodal point-of-need manufacturing capability.
Single-platform systems have proven capable of producing a wide range of proteins due to advancements in lysate production, scaling, and automation2. However, ensuring consistent batch quality and reproducibility that meet regulatory standards remains the primary hurdle for widespread adoption of portable protein production. Integrated analytics coupled with machine learning may offer a solution by providing unprecedented levels of batch purity and consistency.
Phase I:
The objective of Phase I is to conduct a feasibility study using an existing BOND platform. This activity may include producing high purity proteins with consistency, advancing glycosylation approaches, developing lysate, exploring AI/ML process analytic techniques, or proposing novel anti-infectious biologics. Successful completion of Phase I should provide evidence that a higher Technology Readiness Level maybe achieved with a specified platform.
Phase II:
This solicitation seeks proposals for a robust, portable biologics-on-demand system capable of producing GMP-like protein. Offerors must demonstrate a ruggedized BOND platform with reproducible, scalable, and high-quality throughput. Proposed solutions may involve (but are not limited to) developing ML/AI processing, sensor validation, lysate optimization, and resin modification. Final demonstration should include the production of weekly batches with verification of consistent product quality.
Phase III:
PHASE III: The end goal of Phase III will be a BOND device capable of producing GMP-like proteins and ready for FDA evaluation. Such activities may include manufacturing replicate platforms and conducting multiple batch runs for product evaluation. A successful outcome of PHASE III will be to demonstrate that the BOND device is capable of meeting or surpassing existing production methods of a currently approved FDA protein.
Files
| File | Type | Posted |
|---|---|---|
| CBD254-011.pdf | ||
| CBD_SBIR_25.4_R12.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity